Lilly three-year tirzepatide results show sustained weight loss, diabetes benefits
by
Contributor since / Followers
Contributor since / Followers
1 month ago
jetcityimage/iStock Editorial via Getty Images
- More detailed results from Eli Lilly’s (NYSE:LLY) three-year, phase 3 SURMOUNT-1 study showed that tirzepatide, the active ingredient in its obesity and type 2 diabetes meds, respectively, Wegovy and Ozempic, led to sustained weight loss and diabetes benefits.
- After three years and those given the 15 mg dose — the highest one tested — saw a sustained average weight loss of 22.9%.
- Across all three doses tested, tirzepatide compared to placebo was associated with a 94% risk reduction of progression to diabetes.
- The roughly 1,000 patients enrolled in the trial were pre-diabetic and considered either obese or overweight. They were randomized to receive one of the three doses or placebo.
- Lilly noted that in absolute terms, 99% of those on tirzepatide remained free of diabetes over three years.
- The SURMOUNT-1 results released today build on those released in August.